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Juvenile Sjögren’s Syndrome: Clinical Characteristics With 
Focus on Salivary Gland Ultrasonography
Daniel S. Hammenfors,1 Valéria Valim,2 Blanca E. R. G. Bica,3 Sandra G. Pasoto,4 Vibke Lilleby,5  
Juan Carlos Nieto-González,6  Clovis A. Silva,4 Esther Mossel,7 Rosa M. R. Pereira,4 Aline Coelho,2 
Hendrika Bootsma,7 Akaluck Thatayatikom,8 Johan G. Brun,1 and Malin V. Jonsson9
Objective. Juvenile Sjögren’s syndrome (SS) is a rare, poorly defined, and possibly underdiagnosed condition 
 affecting children and adolescents. The aim of this study was to characterize symptoms and clinical findings of juvenile 
SS and to explore the clinical application of major salivary gland ultrasonography (SGUS) in patients with juvenile SS.
Methods. A cross- sectional multicenter study recruited patients with disease onset until age 18 years (n = 67). 
Disease characteristics were recorded, and unstimulated whole sialometry and SGUS examination of the parotid and 
submandibular salivary glands were performed.
Results. The female:male ratio was 58:9. The mean age at first symptom was 10.2 years and 12.1 years at 
diagnosis. Ocular and oral symptoms were noted in 42 of 67 patients (63%) and 53 of 66 patients (80%), respec-
tively. The American- European Consensus Group or American College of Rheumatology/European League Against 
Rheumatism classification criteria for primary SS were fulfilled by 42 of 67 patients (63%). Pathologic SGUS findings 
were observed in 41 of 67 patients (61%); 26 of 41 SGUS+ patients (63%) fulfilled primary SS criteria. Salivary gland 
enlargements/parotitis were noted in 37 of 58 patients and were nonsignificantly associated with SGUS+ status (P 
= 0.066). The mean levels of saliva were 5.6 ml/15 minutes in SGUS– patients compared to 3.3 ml/15 minutes in 
the SGUS+ patients (P = 0.049). A total of 36 of 41 SGUS+ patients (88%) were anti- Ro/La+ compared to 14 of 26 
SGUS– patients (54%) (P = 0.001). In addition, 24 of 39 SGUS+ patients (62%) were positive for rheumatoid factor 
(RF), whereas only 5 of 25 SGUS– patients (20%) were RF+ (P = 0.001).
Conclusion. Juvenile SS is characterized by a large spectrum of clinical symptoms and findings. Several glandu-
lar and extraglandular parameters such as hyposalivation, swollen salivary glands, and autoantibodies are associated 
with pathologic SGUS findings.
INTRODUCTION
Primary Sjögren’s syndrome (SS) is a systemic autoimmune 
disorder. Patients with primary SS experience oral and ocular dry-
ness and extraglandular manifestations such as fatigue, arthralgia, 
and arthritis (1). In addition to subjective and objective findings 
of salivary and/or lacrimal gland involvement, the primary SS 
classification is based on either the presence of autoantibodies 
against Ro/SSA and/or La/SSB, and/or focal mononuclear cell 
 inflammation with a focus score ≥1 in a minor labial salivary gland 
biopsy (2). Serum autoantibodies have been presented as early 
markers of primary SS (3).
Juvenile SS is a rare, poorly defined and possibly underdi-
agnosed condition (4,5). The mean age at the time of diagno-
sis is approximately 10 years (6). A common initial symptom is 
swelling of the major salivary glands (6,7). Several organ systems 
may be affected, resulting in neurologic, dermatologic, musculo-
skeletal, vascular, gastrointestinal, respiratory, renal, and hema-
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tologic manifestations (8,9). Extraglandular manifestations occur 
in approximately 50% of children with juvenile SS (4). Criteria for 
juvenile SS are not available in current literature (10–12), and nei-
ther the American- European Consensus Group (AECG) criteria 
(2) nor the American College of Rheumatology (ACR)/European 
League Against Rheumatism (EULAR) criteria (13) have been 
validated in a juvenile population. In addition, the AECG criteria 
may not be applicable due to diverse clinical manifestations in 
children compared to adults (5).
Interest regarding the major salivary glands ultrasonogra-
phy examination (SGUS) (14) as a diagnostic tool for primary 
SS is increasing (15–19). SGUS may serve as a supplement, 
or even alternative, to minor salivary gland biopsy (11,17). 
Development of a noninvasive, diagnostic method for evalu-
ation of the salivary gland component, to aid the diagnosis of 
juvenile SS, is especially important in the younger population, 
both with regard to the late onset in some patients of sicca 
symptoms and the current lack of diagnostic criteria. Previous 
studies have indicated that SGUS may be of value in establish-
ing a juvenile SS diagnosis (7,20,21). However, current reports 
include small numbers of patients, and SGUS application 
remains to be evaluated in a larger cohort. Further studies on 
juvenile SS are needed, and to our knowledge, our study is, 
to date, the largest cohort for this patient group. The aim of 
this study was to characterize symptoms and clinical findings 
in patients with juvenile SS and to investigate SGUS as a diag-
nostic tool for juvenile SS.
MATERIALS AND METHODS
Patients. The study design was a cross- sectional 
multicenter study. Patients were recruited from Haukeland 
University Hospital in Bergen, Norway, Oslo University Hos-
pital in Oslo, Norway, Hospital General Universitario Grego-
rio Marañón in Madrid, Spain, Hospital Universitário Cassiano 
Antônio Moraes of Federal University of Espírito Santo in 
Vitória, Brazil, Hospital Universitário Clementino Fraga Filho of 
Federal University of Rio de Janeiro in Rio de Janeiro, Brazil, 
Hospital das Clinicas, Faculdade de Medicina da Universidade 
de Sao Paulo in Sao Paulo, Brazil, University Medical Center 
Groningen in Groningen, The Netherlands, and University of 
Florida, Gainesville, Florida. Patients had previously received 
the diagnosis of juvenile SS by a specialist in rheumatology 
or pediatric medicine at age ≤18 years. At the time of inclu-
sion, all patients were younger than 25 years. Identification of 
patients at each clinic was performed by the local specialist in 
rheumatology or pediatric medicine.
A clinical examination, sialometry, and SGUS were per-
formed in all patients. Upon inclusion, patients were asked for 
information on extraglandular manifestations, and a medical 
history was collected from medical charts, including informa-
tion regarding autoantibodies, biopsy results, and current/pre-
vious treatment.
Patients recruited in Norway (n = 11), Spain (n = 5), and 
Brazil (n = 40) were examined and included by the primary 
investigators (SDH and MVJ) with the local specialist. Patients 
recruited from The Netherlands (n = 8) and US (n = 3) were 
examined in collaboration with local experts and included ret-
rospectively. Because this was a cross- sectional study, not all 
clinical examinations and tests had been performed or were 
available in all patients.
Disease activity measurements. Subjective symp-
toms and the EULAR Sjögren’s Syndrome Patient Reported 
Index (ESSPRI) score (22) were determined upon inclusion. 
Children were aided by an accompanying parent/guardian, 
when necessary. The European League Against Rheumatism 
Sjögren’s Syndrome Disease Activity Index (ESSDAI) score 
(23) was registered upon inclusion. The hematologic and bio-
logic domains were determined from the most recent blood 
samples available.
Tear secretion. Tear secretion was evaluated by the 
Schirmer I test. Wetting of the strip was recorded in mm, with 
levels of ≤5 mm wetting of the paper strip considered as patho-
logically reduced tear secretion.
Sialometry. Salivary gland functional capacity was eval-
uated by unstimulated sialometry, measured in ml/15 minutes, 
with the patients fasting for 90 minutes prior to examination. The 
volume of saliva was determined by weighing, with 1 gram cor-
responding to 1 ml. Saliva secretion levels ≤1.5 ml/15 minutes 
were considered pathologically reduced.
Salivary gland ultrasonography. The SGUS examina-
tion of the parotid and submandibular glands was performed 
using linear high- frequency transducers (6–15 MHz) and a sim-
plified scoring system. Glandular homogeneity and the presence 
of hypoechogenic areas were evaluated and graded (range 0–3). 
Grades 0–1 were considered to correspond to normal/non-
specific changes and grades 2–3 to correspond to pathologic 
changes (Figure 1). The SGUS was performed and scored bed-
side by local experts in the US and The Netherlands and by SDH 
and MVJ in Norway, Spain, and Brazil.
SIGNIFICANCE & INNOVATIONS
• Interest in juvenile Sjögren’s syndrome is increas-
ing and international collaborations are emerging. 
To date, to the best of our knowledge, this is the 
largest cohort world-wide characterizing juvenile 
Sjögren’s syndrome and also the first large study 
investigating salivary gland ultrasonography in this 
patient group.
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Ethical considerations. This study was performed in 
accord with the regional medical and health research ethics 
regulations, and necessary applications were approved by 
the regional Committees in the participating centers/coun-
tries (Norway: 145/96- 44.96, 242.06 2009/686; Brazil: 4478
701544787015447870151.433.660/201644787015.6.2001.
0068). Informed consent was obtained from all participants 
and from parents of patients age <16 years, according to the 
Declaration of Helsinki. Parents/legal guardians of underaged 
patients were present at inclusion (clinical examination and 
SGUS imaging). In Spain, The Netherlands, and US, the non-
invasive study design and number of patients included were in 
accordance with regional ethical guidelines and did not need a 
specific project approval.
Statistical analysis. Student’s t- test with Welch’s correc-
tion was used to study differences between groups and Pearson’s 
correlation for the relationship between 2 variables. Correlations 
within ranges 0.0 to <0.2 were considered as poor, 0.2 to <0.4 
as fair, 0.4 to <0.6 as moderate, 0.6 to <0.8 as good, and 0.8–
1.0 as excellent. For categorical data, chi- square analysis was 
employed. To adjust for Type I error due to multiple comparisons, 
Benjamin- Hochberg adjustment was applied. All analyses were 
performed using SPSS statistics software, version 19.0.
Figure 1. Representative major salivary gland ultrasonography images of submandibular glands, illustrating A, grade 0; B, grade 1; C, grade 
2; and D, grade 3, with grades 0–1 corresponding to normal- appearing morphology, and grades 2–3 corresponding to pathologic changes in 
the submandibular and parotid glands of patients with clinical symptoms of juvenile Sjögren’s syndrome.
Table 1. Patient demographics and associated diseases in all included patients (n = 67) with a clinical diagnosis of juvenile 
Sjögren’s syndrome*
No.
Mean ± SD 
years SGUS– SGUS+ P†
Benjamin- Hochberg 
adjustment
Age at inclusion, years 67 16.3 ± 4.7‡ 17.3 ± 5.7 15.6 ± 3.9 0.146 NS
Age at first symptom, years 64§ 10.2 ± 3.7 10.5 ± 4.5 10.1 ± 3.2 0.675 NS
Age at diagnosis, years 61§ 12.1 ± 3.8 12.0 ± 4.5 12.2 ± 3.3 0.875 NS
Time from symptom onset to 
diagnosis, years
60§ 1.8 ± 1.9 1.5 ± 1.5 1.9 ± 2.0 0.355 NS
Time from diagnosis to 
inclusion, years
61§ 4.1 ± 4.4‡ 5.5 ± 5.3 3.3 ± 3.5 0.062 NS
Female:male ratio 58:9 – 25:1 33:8 0.067 NS
Hypothyroidism, no./total (%)¶ 5/59 (8) – 3/25 (12) 2/34 (6) 0.404 NS
SLE, no./total (%)¶ 7/59 (12) – 4/25 (16) 3/34 (9) 0.400 NS
MCTD, no./total (%)¶ 1/59 (2) – 1/25 (4) 0/34 (0) 0.240 NS
* Values are the mean ± SD unless indicated otherwise. SGUS = salivary gland ultrasonography; NS = nonsignificant; 
SLE = systemic lupus erythematosus; MCTD = mixed connective tissue disease. 
† P values are for the comparison of SGUS+ and SGUS– patients. 
‡ Regional differences (patients included in Brazil compared to patients included in Europe/US). 
§ Data not available from all patients. 
¶ Number of positive observations/number of available observations. 
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RESULTS
Patient characteristics. Our cohort consisted of 67 
patients. The female:male ratio was 58:9. Mean age at first symp-
tom was 10.2 years (range 1–17), with 12.1 years at diagnosis 
(range 4–18), and 16.3 years at inclusion (range 6–25) (Table 1).
Of the 67 patients, 35 (52%) and 39 (58%) fulfilled the AECG 
(2) and ACR/EULAR (13) classification criteria, respectively. 
When combining the criteria, 32 patients (48%) fulfilled both sets 
of criteria and 42 patients (63%) fulfilled either the AECG or the 
ACR/EULAR criteria. One patient had mixed connective tissue 
disease (MCTD), and 7 patients were diagnosed with systemic 
lupus erythematosus (SLE) (Table 1).
In the patients with MCTD/SLE (n = 8), 7 presented with 
autoantibodies and fulfilled the AECG and the ACR/EULAR 
 classification criteria. In this subgroup, 6 of 8 patients had ocular 
symptoms and 5 had ocular signs. All patients had experienced 
major salivary gland swelling, and 6 had salivary gland involve-
ment by sialometry (n = 2), scintigraphy (n = 2), sialometry and 
scintigraphy (n = 1), or sialometry, scintigraphy, and sialography 
(n = 1). Five had available minor salivary gland biopsy results; the 
3 patients lacking biopsy results had objective evidence of salivary 
gland involvement, either by a positive scintigraphy (n = 1), sia-
lometry and scintigraphy (n = 1), or sialometry, scintigraphy, and 
sialography (n = 1). All 5 biopsy results were positive, i.e., with a 
focus score of ≥1, corresponding to ≥1 chronic inflammatory cell 
foci consisting of 50 or more cells per 4 mm2 of otherwise normal- 
appearing minor salivary gland tissue. In comparison, for the 
remaining patients not diagnosed with an additional connective 
tissue disease (n = 59), information on minor salivary gland biopsy 
Table  2. Subjective ocular and oral symptoms, objective signs of impaired tear secretion, salivary gland inflammation and 
hypofunction, serum autoantibodies, and fulfillment of classification criteria in all included patients (n = 67) with juvenile Sjögren’s 
syndrome*
No. SGUS– SGUS+ P†
Benjamin- Hochberg 
adjustment
Ocular symptoms (I) 42/67 (63)‡ 23/26 (88) 19/41 (46) 0.001 Significant
Oral symptoms (II) 53/66 (80) 18/26 (69) 30/40 (75) 0.607 NS
Salivary gland enlargement 37/58 (64)§ 12/24 (50) 25/34 (74) 0.066 NS
Ocular signs (III) 33/65 (51)‡ 16/24 (67) 17/41 (41) 0.05 NS
Schirmer I test (ever) 27/64 (42)¶ 13/25 (52) 14/39 (36) 0.203 NS
Ocular staining score 20/37 (54) 12/18 (67) 8/19 (42) 0.134 NS
Focus score ≥1 (IV) 28/34 (82) 7/8 (88) 21/26 (81) 0.662 NS
Focus score, mean ± SD 1.7 ± 1.7 
(n = 20)
1.0 ± 0 1.9 ± 1.9 0.368 NS
Salivary gland involvement (V) 41/61 (67)# 21/26 (81) 20/35 (57) 0.052 NS
UWS ≤1.5 ml/minute 20/60 (33)¶ 9/26 (35) 11/34 (32) 0.854 NS
UWS, mean ± SD ml/15 
minutes
4.3 ± 4.6 
(n = 60)
5.6 ± 5.8 3.3 ± 3.2 0.049 NS
Sialography 1/3 (33)** 1/2 (50) 0/1 (0) 0.386 NS
Sialo- scintigraphy 29/31 (9)†† 20/22 (91) 9/9 (100) 0.350 NS
SGUS 41/67 (61)‡‡ – – – –
Autoantibodies (VI) 50/67 (75)‡ 14/26 (54) 36/41 (88) 0.002 Significant
ANA 62/67 (93)§ 23/26 (88) 39/41 (9) 0.312 NS
Anti- Ro/SSA 50/67 (75)§§ 14/26 (54) 36/41 (88) 0.002 Significant
Anti- La/SSB 27/67 (40)‡‡ 4/26 (15) 23/41 (56) 0.001 Significant
Anti- Ro/SSA and anti- La/SSB 27/67 (40)‡‡ 4/26 (15) 23/41 (56) 0.001 Significant
Anti- Ro/SSA or anti- La/SSB 50/67 (75)§§ 14/26 (54) 36/41 (88) 0.002 Significant
Rheumatoid factor 29/64 (45)‡ 5/25 (20) 24/39 (62) 0.001 Significant
AECG criteria 35/67 (52) 14/26 (54) 21/41 (51) 0.834 NS
ACR/EULAR criteria 39/67 (58) 15/26 (58) 24/41 (59) 0.946 NS
ACR/EULAR and AECG criteria 32/67 (48) 13/26 (50) 19/41 (46) 0.770 NS
ACR/EULAR or AECG criteria 42/67 (63) 16/26 (62) 26/41 (63) 0.877 NS
* Values are the number of patients with positive findings/patients with available information (%), unless indicated otherwise. 
 Roman numerals indicate the corresponding items of the American- European Consensus Group (AECG) criteria. Regional differ-
ences refer to patients included in Brazil compared to patients included in Europe/US. SGUS = salivary gland ultrasonography; NS 
= nonsignificant; UWS = unstimulated whole saliva flow; ANA = antinuclear antibody; ACR = American College of Rheumatology; 
EULAR = European League Against Rheumatism. 
† P values are for the comparison of SGUS+ and SGUS– patients. 
‡ Regional differences. 
§ Eight patients with systemic lupus erythematosus (SLE)/mixed connective tissue disease (MCTD). 
¶ Four patients with SLE/MCTD. 
# Six patients with SLE/MCTD, and 5 patients with SLE/MCTD, with regional differences. 
** One patient with SLE/MCTD, with regional differences. 
†† Four patients with SLE/MCTD, with regional differences. 
‡‡ Three patients with SLE/MCTD, with regional differences. 
§§ Seven patients with SLE/MCTD, with regional differences. 
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results was available from 29 patients, with a positive biopsy result 
in 23 cases. Among these, the accurate focus score was available 
from 16 patients, and 15 biopsy results were positive (focus score 
≥1). All MCTD/SLE patients had extraglandular manifestations 
and 3 had renal affection, findings that were not registered in any 
of the other patients.
Subjective symptoms. Subjective ocular and oral dryness 
symptoms were noted in 42 of 67 patients (63%) and 53 of 66 
patients (80%), respectively (Table 2). Only 8 of 66 patients (12%) 
reported no dryness symptoms. Ocular signs were noted in 26 of 
40 patients (65%) with ocular symptoms (P = 0.004).
Subjective oral symptoms were not associated with a posi-
tive minor salivary gland biopsy result or objective salivary gland 
involvement (sialometry, sialography, or scintigraphy). Sialo- 
scintigraphy and/or sialography had been performed in 31 
patients (Table 2), although only in the Brazilian part of the cohort.
The ESSPRI score for dryness correlated nonsignificantly 
with age at inclusion (P = 0.062; n = 58). The mean ESSPRI score 
for patients not fulfilling classification criteria (n = 25) was 2.7 com-
pared to 4.0 for patients (n = 40) fulfilling either AECG and/or ACR/
EULAR classification criteria for primary SS (P = 0.04).
Major salivary gland imaging and glandular 
 characteristics. Pathologic SGUS findings (Figure 1 C and D) 
were observed in 41 of 67 patients. The mode SGUS score was 2 
for all glands. The total sum of the SGUS score for all 4 glands (range 
0–12) correlated with the ACR/EULAR points (r = 0.321, P = 0.016; 
n = 56) (Figure 2). SGUS+ findings were observed in 26 of 27 of 
the European and North American patients as compared to 15 of 
40 of the Brazilian patients (P = 0.001).
Subjective sicca symptoms were not associated with patho-
logic SGUS findings; ocular symptoms were noted only in 19 of 
41 SGUS+ patients (46%) compared to 23 of 26 SGUS– patients 
(88%) (P = 0.001). Ocular signs were noted in 17 of 41 SGUS+ 
patients (41%) compared to 16 of 24 SGUS– patients (67%) 
(P = 0.050). Oral symptoms were noted in 30 of 40 SGUS+ patients 
(75%) compared to 18 of 26 SGUS– patients (69%) (P = 0.607).
Salivary gland involvement (sialometry, sialo- scintigraphy, 
and sialography) was noted in 41 of 61 patients (67%), 20 of 
35 SGUS+ patients (57%), and 21 of 26 SGUS– patients (81%) 
(P = 0.052) (Table 2). When considering the individual items for 
salivary gland involvement, unstimulated whole saliva levels 
(ml/15 minutes) correlated inversely with the sum of the SGUS 
score (range 0–12) for all 4 glands (r = –0.324, P = 0.015 [n = 56]) 
 (Figure 2), and with the SGUS score (range 0–3) for both subman-
dibular glands (r = –0.372, P = 0.005 [n = 56], and r = –0.301, 
P = 0.024 [n = 56], right and left gland, respectively). A corre-
lation was also observed in the right parotid gland (r = –0.285, 
P = 0.033 [n = 56]). The mean level of saliva was 5.6 ml/15 minutes 
Figure 2. Total major salivary gland ultrasonography score (range 
0–12) for all 4 glands in relation to the A, Total points of the American 
College of Rheumatology/European League Against Rheumatism 
classification criteria (range 0–9) (P = 0.016), B, Focus score, and 
C,  Unstimulated whole saliva flow (range 0–21.36 ml/15 minute) 
(P = 0.015). The correlations were not significant after Benjamin- 
Hochberg adjustment. We did not find a correlation with the focus 
score (range 0–8).
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in SGUS– patients compared to 3.3 ml/15 minutes in the SGUS+ 
patients (P = 0.049), but when comparing saliva cutoff levels (≤1.5 
ml/15 minutes) SGUS+ patients were below the threshold in 11 
of 34 cases (32%), compared to 9 of 26 SGUS– patients (35%) 
(P = 0.854). Scintigraphy findings coincided with both normal and 
pathologic SGUS findings (P = 0.350) (Table 2).
Information regarding minor labial salivary gland biopsy results 
was available in 34 patients. Among these, 28 of 34 patients (82%) 
had a focus score ≥1, 21 of 26 SGUS+ patients (81%) compared to 
7 of 8 SGUS– patients (88%) (P = 0.662) (Table 2). For 20 patients, 
the precise focus score was available, ranging from 0 to 8 with a 
mean of 1.7. The mean focus score was 1.9 in the SGUS+ patients 
(n = 16) compared to 1.0 in the SGUS– patients (n = 4), but the 
difference was not statistically significant (P = 0.368), most likely 
due to low numbers. Low numbers probably also influenced the 
lack of correlation between precise focus score and total SGUS 
score, both when considering the glands separately and for all 
glands (Figure 2).
In total, 37 of 58 patients (64%) had experienced salivary 
gland enlargements/parotitis (Table 2), and although not significant, 
a trend was noted with regard to pathologic SGUS findings; 25 of 
34 SGUS+ patients (74%) had experienced salivary gland swelling, 
compared to 12 of 24 SGUS– patients (50%) (P = 0.066).
Autoantibodies. The majority of patients, 50 of 67 (75%), 
presented with anti- Ro/SSA and/or anti- La/SSB. In the group with 
SGUS+ findings, 36 of 41 patients (88%) were anti- Ro/SSA positive, 
whereas in the SGUS– group only 14 of 26 patients (54%) were 
anti- Ro/SSA positive (P = 0.002). Similarly, SGUS+ status was asso-
ciated with anti- La/SSB; 23 of 41 of the SGUS+ patients (56%) were 
anti- La/SSB+, whereas only 4 of 26 of the SGUS– patients (15%) 
were anti- La/SSB+ (P = 0.001), and 24 of 39 of the SGUS+ patients 
(62%) were positive for rheumatoid factor (RF), whereas only 5 of 25 
of the SGUS– patients (20%) were RF+ (P = 0.001) (Table 2).
In total, 11 of 36 SGUS+ patients (31%) with positive 
anti- Ro/SSA status did not fulfill the current classification cri-
teria for primary SS (2,13). Of these 11 patients, all did not 
fulfill or were lacking 1 or several items; ocular symptoms 
(n = 11, 3 positive), oral symptoms (n = 10, 7 positive), ocu-
lar signs (n = 11, all negative), minor salivary gland biopsy 
Table 3. Extraglandular manifestations in patients with juvenile Sjögren’s syndrome*
No. SGUS– SGUS+ P†
Benjamin- Hochberg 
adjustment
Extraglandular manifestations 56/62 (90)‡ 24/25 (96) 32/37 (86) 0.214 NS
Constitutional 24/59 (41)§ 12/25 (48) 12/34 (35) 0.326 NS
Cutaneous 17/59 (29)¶ 8/25 (32) 9/34 (26) 0.643 NS
Lymphadenopathy 35/59 (59)# 17/25 (68) 18/34 (53) 0.245 NS
Articular 34/59 (58)** 17/25 (68) 17/34 (50) 0.167 NS
Muscular 5/59 (8) 1/25 (4) 4/34 (12) 0.290 NS
Pulmonary 1/59 (2) 1/25 (4) 0/34 (0) 0.240 NS
Renal 3/59 (5)†† 1/25 (4) 2/34 (6) 0.745 NS
Peripheral nervous system 1/59 (2) 1/25 (4) 0/34 (0) 0.240 NS
Central nervous system 3/59 (5) 3/25 (12) 0/34 (0) 0.038 NS
Hematologic domain 16/58 (28)¶ 6/24 (25) 10/34 (29) 0.711 NS
Biologic domain 21/58 (36)‡‡ 9/24 (38) 12/34 (35) 0.863 NS
ESSPRI score, mean ± SD 3.5 ± 2.5 
(n = 65)
3.2 ± 2.8 3.7 ± 2.3 0.368 NS
ESSPRI dryness, mean ± SD 3.4 ± 3.0 
(n = 65)
3.4 ± 2.9 3.5 ± 3.1 0.919 NS
ESSPRI fatigue, mean ± SD 4.3 ± 3.4 
(n = 65)§§
3.8 ± 3.9 4.6 ± 3.0 0.314 NS
ESSPRI pain, mean ± SD 2.9 ± 3.2 
(n = 65)
2.4 ± 3.4 3.2 ± 3.2 0.362 NS
Total ESSDAI score, mean ± SD 4.7 ± 5.4 
(n = 62)
3.4 ± 2.8 5.5 ± 6.5 0.138 NS
Clinical ESSDAI, mean ± SD 3.2 ± 4.1 
(n = 59)
2.7 ± 3.0 3.6 ± 4.8 0.443 NS
* Values are the number of patients with positive findings/patients with available information (%), unless indicated other-
wise. Regional differences refer to patients included in Brazil compared to patients included in Europe/US. SGUS = salivary 
gland ultrasonography; NS = nonsignificant; ESSPRI = European League Against Rheumatism (EULAR) Sjögren’s Syndrome 
Patients Reported Index; ESSDAI = EULAR Primary Sjögren’s Syndrome Disease Activity Index. 
† P values are for the comparison of SGUS+ and SGUS– patients. 
‡ Eight patients with systemic lupus erythematosus (SLE)/mixed connective tissue disease (MCTD), with regional differences. 
§ Five patients with SLE/MCTD, with regional differences. 
¶ Five patients with SLE/MCTD. 
# Three patients with SLE/MCTD, with regional differences. 
** Eight patients with SLE/MCTD. 
†† Three patients with SLE/MCTD. 
‡‡ Six patients with SLE/MCTD. 
§§ Regional differences. 
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(n = 3, all negative), salivary gland involvement (n = 6, 2 pos-
itive), sialo- scintigraphy (n = 1, positive), sialometry (n = 6, all 
negative), ocular staining score (n = 6, 1 positive). Six patients 
had experienced salivary gland swelling; 2 of these had also 
experienced lacrimal gland swelling.
Taking a closer look at patients not fulfilling classifica-
tion criteria for primary SS (n = 25), 11 of 25 patients (44%) 
presented with anti- Ro/SSA and SGUS+ status, whereas the 
remaining patients (n = 14) were either SGUS+ but lacked 
anti- Ro/SSA (n = 4) or were anti- Ro/SSA– and had a normal- 
appearing SGUS (n = 10). Among the SGUS+/anti- Ro/SSA– 
patients, 2 of 4 were positive for antinuclear antibody (ANA). 
For the SGUS–/anti-Ro/SSA– patients, all had pathologic 
findings by sialo- scintigraphy, 9 of 10 (90%) were ANA+, 3 of 
10 (30%) had pathologic levels of unstimulated whole saliva 
flow, and 1 also had a positive sialography. One of the SGUS–/
anti- Ro/SSA– patients was diagnosed with SLE.
Extraglandular manifestations. Various extraglandular 
manifestations at some time point had been noted in 56 of 62 
patients (90%) (Table 3). The mean ESSPRI score total was 4.0 
for patients (n = 40) fulfilling classification criteria for primary SS 
(2,13) compared to 2.7 for the remaining patients (n = 25) (P = 
0.040). The ESSPRI pain score was also increased in patients ful-
filling the AECG and/or ACR/EULAR classification criteria for pri-
mary SS, with mean levels of 3.5 compared to 1.9 (P = 0.05). The 
mean ESSDAI score was nonsignificantly higher in the SGUS+ 
patients compared to the SGUS– patients (P = 0.138) (Table 3).
Treatment. Symptomatic treatment was observed in 29 of 
59 patients (49%) (Table 4). Symptomatic treatment was registered 
in 16 of 34 SGUS+ patients (47%) compared to 17 of 25 SGUS– 
patients (68%) (P = 0.109). Only 5 of 59 patients (8%) had received 
salivary substitutes; 4 of these patients had SGUS+ status. Three 
patients had received pilocarpine, none had received cevimeline. 
A higher number of patients, 30 of 59 (51%), had received or were 
using lacrimal substitutes, whereof the majority, 18 of 30 (60%), had 
normal SGUS (P = 0.005) (Table 4). The mean ESSPRI score for 
dryness was 4.1 for patients who had received symptomatic treat-
ment compared to 2.4 for those without symptomatic treatment 
(P = 0.028).
Current or previous use of nonsteroidal antiinflammatory drugs 
was noted in 16 of 34 SGUS+ patients (47%) compared to 9 of 25 
SGUS– patients (36%) (P = 0.396). Of 59 patients, 54 were currently 
Table 4. Treatment in all included patients with juvenile Sjögren’s syndrome*
No. SGUS– SGUS+ P†
Benjamin- Hochberg 
adjustment
Symptomatic treatment, current 29/59 (49)‡ 17/25 (68) 16/34 (47) 0.109 NS
Symptomatic treatment, ever 47/59 (80)§ 22/25 (88) 25/34 (74) 0.172 NS
Salivary substitutes, current 4/59 (7) 1/25 (4) 3/34 (9) 0.466 NS
Salivary substitutes, ever 5/59 (8) 1/25 (4) 4/34 (12) 0.466 NS
Lacrimal substitutes, current 25/59 (42)¶ 16/25 (64) 9/34 (26) 0.004 Significant
Lacrimal substitutes, ever 30/59 (51)¶ 18/25 (72) 12/34 (35) 0.005 Significant
NSAIDS, current 9/59 (15) 1/25 (4) 8/34 (24) 0.039 NS
NSAIDs, ever 25/59 (42)# 9/25 (36) 16/34 (47) 0.396 NS
Systemic treatment, ever 56/59 (95)** 25/25 (100) 31/34 (91) 0.127 NS
Systemic treatment, current 46/59 (78)†† 23/25 (92) 23/34 (68) 0.026 NS
Hydroxychloroquine, ever 54/59 (92)** 25/25 (100) 29/34 (85) 0.045 NS
Hydroxychloroquine, current 40/59 (68)** 22/25 (88) 18/34 (53) 0.004 Significant
MTX, ever 22/57 (39)# 9/25 (36) 13/32 (41) 0.722 NS
MTX, current 14/57 (25)# 6/25 (24) 8/32 (25) 0.931 NS
Azathioprine, ever 12/58 (21)‡‡ 6/25 (24) 6/33 (18) 0.588 NS
Azathioprine, current 10/58 (17)§§ 5/25 (20) 5/33 (15) 0.628 NS
Low prednisone, ever 31/57 (54)§ 11/24 (46) 20/33 (61) 0.269 NS
Low prednisone, current 12/57 (21)¶¶ 4/24 (17) 8/33 (24) 0.489 NS
High prednisone, ever 13/59 (22)‡ 6/25 (24) 7/34 (21) 0.755 NS
High prednisone, current 5/59 (8)§§ 2/25 (8) 3/34 (9) 0.911 NS
* Values are the number of patients with positive findings/patients with available information (%), unless indicated 
 otherwise. Regional differences refer to patients included in Brazil compared to patients included in Europe/US. SGUS = 
salivary gland ultrasonography; NS = nonsignificant; NSAIDs = nonsteroidal antiinflammatory drugs; MTX = methotrexate. 
† P values are for the comparison of SGUS+ and SGUS– patients. 
‡ Six patients with systemic lupus erythematosus (SLE)/mixed connective tissue disease (MCTD), with regional differ-
ences. 
§ Six patients with SLE/MCTD. 
¶ Five patients with SLE/MCTD, with regional differences. 
# One patient with SLE/MCTD. 
** Eight patients with SLE/MCTD. 
†† Eight patients with SLE/MCTD, with regional differences. 
‡‡ Four patients with SLE/MCTD, with regional differences. 
§§ Four patients with SLE/MCTD. 
¶¶ Five patients with SLE/MCTD. 
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(n = 40) or previously (n = 14) treated with hydroxychloroquine. In 
total, 29 of 34 SGUS+ patients (85%) had experience using hydroxy-
chloroquine, whereas 25 of 25 SGUS– patients had used or were 
using hydroxychloroquine (P = 0.045). When instead comparing 
never users (n = 5) and previous users (n = 14) to current users 
(n = 40), 18 of 34 SGUS+ patients (53%) and 22 of 25 SGUS– 
patients (88%) were on current treatment (P = 0.004) (Table 4).
Systemic treatment was noted in 56 of 59 patients (95%) 
and was associated with extraglandular manifestations in 52 of 
53 patients (P = 0.001). In 10 patients, systemic treatment was 
ceased, and 42 of 53 patients with extraglandular manifestations 
were currently receiving systemic treatment (P = 0.481). In 40 of 
46 patients (87%), the systemic treatment was current hydroxy-
chloroquine (P = 0.001).
DISCUSSION
To date, this is the largest study investigating clinical charac-
teristics of patients with juvenile SS in combination with SGUS. 
The female:male ratio was approximately 6.4:1, i.e., slightly 
altered with more male patients as compared to 9:1 for adults 
with primary SS (24–27). The mean time from symptom debut to 
diagnosis was 1.8 years, naturally shorter than in adult primary 
SS patients, where the time from debut of symptoms to diagno-
sis spans up to 11–14 years (26).
Nearly 2 of 3 of the patients fulfilled the current classifications 
criteria for primary SS, and there were no significant differences in 
the application of the 2002 AECG (2) and the ACR/EULAR criteria 
(13). Due to different practices between regions and the fact that 
not all examinations in the classification criteria are routinely per-
formed in all pediatric patients, we cannot be certain that patients 
not fulfilling the classification criteria in this study would still not fulfill 
criteria were all necessary examinations performed.
SGUS findings were associated with anti- Ro/SSA and 
anti- La/SSB, similar to previous findings in adult primary SS (28). 
Of the 36 SGUS+ patients with positive anti- Ro/SSA, 11 patients 
did not fulfill the AECG or ACR/EULAR classification criteria due 
to lack of objective salivary or lacrimal gland involvement, such as 
reduced salivary and/or lacrimal secretion. Of these 11 patients, 6 
of 8 had registered salivary gland enlargement.
When considering the patients not fulfilling classification 
criteria for primary SS (n = 25), 11 (44%) were anti- Ro/SSA+ 
and SGUS+, 4 (16%) were SGUS+ and anti- Ro/SSA–, and 10 
(40%) were anti- Ro/SSA– and SGUS–. Among the anti- Ro/
SSA– patients, 11 of 14 (78.6%) were ANA+. In addition, all 
the anti- Ro/SSA– and SGUS– patients had previously docu-
mented salivary gland involvement by sialo- scintigraphy. Our 
findings thus support the notion that the existing criteria for pri-
mary SS are not optimal for clinical evaluation and research of 
juvenile SS (10,12,29). Of note, among the individuals fulfilling 
either the AECG or the ACR/EULAR classification criteria, 1 of 
42 SGUS+ patients was ANA+ but anti- Ro/SSA–.  Concerning 
the individuals fulfilling both AECG and ACR/EULAR criteria, 
all 19 SGUS+ patients were anti- Ro/SSA+ compared to 11 of 
13 of the SGUS– patients (P = 0.077). Other relevant autoanti-
bodies such as anti- La/SSB and RF were also associated with 
SGUS findings, further supporting the link between autoanti-
bodies and salivary gland involvement in juvenile SS.
In this cohort of patients with juvenile SS, pathologic SGUS 
changes (61%) were slightly more common compared to findings 
in adults (30) and nonsignificantly associated with salivary gland 
swelling, a clinical feature generally associated with juvenile SS. 
Similar to findings in adult primary SS, a higher SGUS score was 
associated with lower levels of unstimulated whole saliva (28), 
nonsignificantly associated with oral dryness symptoms. Treat-
ment of oral dryness symptoms was rare, but linked to SGUS+ 
status in 4 of 5 cases. Ocular sicca symptoms and symptomatic 
treatment of dry eye were more common in SGUS– patients. The 
ESSPRI dryness score showed a trend to increase with age at 
inclusion (P = 0.062). One might speculate whether this increase 
was due to actual later onset of sicca symptoms, or whether oral 
dryness is not perceived as a problem by the younger patients.
Although the mean focus score was higher in SGUS+ 
patients compared to SGUS– patients and implies that the focus 
score can mirror the degree of damage visualized by SGUS, com-
parison of findings in the major and the minor glands was limited 
due to lack of data on minor salivary gland focus score.
Similar to earlier reports in both primary SS and juvenile 
SS, the patients in this cohort displayed a high degree of extra-
glandular manifestations (25,30). Both mean ESSPRI and mean 
ESSPRI pain scores were higher in the patients fulfilling AECG 
and ACR/EULAR classification criteria, and the mean ESSDAI 
score was nonsignificantly higher in the SGUS+ patients com-
pared to the SGUS– patients.
Eight patients with extraglandular manifestations differed from 
their juvenile SS peers in several aspects. All 8 had at some point 
been diagnosed with SLE or MCTD and 3 had renal affection, 
an extraglandular manifestation with a varied prevalence of 2% to 
67% in primary SS (31–33). Kidney involvement was not observed 
in any other patients in the cohort. Although 7 of 8 patients fulfilled 
the classification criteria for primary SS, a possible misdiagnosis 
cannot be ruled out, as differentiation between various connec-
tive tissue diseases can be difficult. Nonetheless, 3 of 8 patients 
with SLE/MCTD presented with SS- like SGUS changes, such as 
hypoechogenic areas and inhomogeneity (27), consistent with the 
frequency of imaging findings in this subgroup of the cohort.
Previous or current systemic treatment was also quite fre-
quent, especially in patients with extraglandular manifestations. 
For the majority of patients, the current systemic treatment was 
hydroxychloroquine. Only 18 of 40 patients with current hydroxy-
chloroquine treatment displayed SGUS+ changes, whereas 16 
of 19 patients without current treatment showed changes. These 
results should, however, be interpreted with care because among 
those 2 groups there is both a higher proportion of patients with 
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extraglandular manifestations (39 of 40 versus 14 of 19, respec-
tively) (P = 0.005), current systemic treatment (37 of 40 versus 9 of 
19, respectively) (P = 0.001), and a lower degree of SGUS+ status 
in a subgroup of the cohort consisting of patients included in Brazil 
compared to Europe/US (15 of 40 versus 26 of 27) (P = 0.000), 
and a possible confounding factor cannot be ruled out. Patients 
in this Brazilian subgroup were also older when included, and the 
mean time from diagnosis to inclusion was higher.
Studying the current group of patients revealed variation in 
subjective symptoms, clinical findings, application of diagnostic 
tests/methods, and treatment regimes. More invasive diagnostic 
methods (such as sialo- scintigraphy and sialography, compared 
to sialometry) and systemic treatment (azathioprine and high dose 
corticosteroids/prednisone) were observed in the subgroup of the 
cohort consisting of patients included in Brazil, possibly due to a 
higher incidence of extraglandular manifestations.
The data presented in this study were a combination of newly 
acquired and retrospective data. In consequence, shortcomings 
include lack of new blood tests and incomplete clinical data, limit-
ing the application of AECG and ACR/EULAR classification crite-
ria. Different ultrasonography machines and probes were used for 
the SGUS examinations, possibly affecting the results obtained. To 
move forward, a prospective study with a more rigorous design, 
a more standardized regime for data collection, and international 
collaborations are necessary to characterize this rare condition 
and establish adequate criteria for diagnosis and classification.
In conclusion, findings in the juvenile SS patients studied indi-
cate an association between SGUS results, hyposalivation, and 
autoantibodies. In many patients, SGUS status was also associ-
ated with salivary gland swelling, a previously known and common 
clinical finding in juvenile SS. SGUS is an interesting diagnostic 
tool for identifying patients with juvenile SS.
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